Results 1 to 10 of about 76,321 (256)

Itch and Janus Kinase Inhibitors

Acta Dermato-Venereologica, 2023
Itch is a common skin symptom, with complex aetiology and pathogenesis. It is mediated by 2 pathways, the histaminergic and non-histaminergic pathways.
Yujin Han, Yu Ri Woo, Sang Hyun Cho, Jeong Deuk Lee, Hei Sung Kim   +4 more
doaj   +3 more sources

Association of Janus kinase 1 and 2 expression with clinical indices in diabetic kidney disease [PDF]

Journal of Research in Medical Sciences
Background: Diabetic Kidney Disease (DKD) is a prevalent complication of uncontrolled hyperglycemia that imposes a considerable burden on the health system due to the need for renal replacement therapy in the long term.
Mahboobeh Freidoon, Naghmeh Sayadi, Sara Assadiasl, Hadi Kazemzadehghadim, Narjes Soleimanifar, Maryam Sadr, Hanieh Mojtahedi, Maryam Ahmadi, Mohammad Hossein Nicknam   +8 more
doaj   +2 more sources

Structural basis of Janus kinase trans-activation

Cell Reports, 2023
Summary: Janus kinases (JAKs) mediate signal transduction downstream of cytokine receptors. Cytokine-dependent dimerization is conveyed across the cell membrane to drive JAK dimerization, trans-phosphorylation, and activation.
Kenan Garcia, Stevan R Hubbard, Caleb R. Glassman   +2 more
exaly   +3 more sources

Evaluation of immunohistochemical and gene expression of Janus kinase 1 and Janus kinase 3 in the skin of different clinical types of mycosis fungoides patients - Part I [PDF]

Anais Brasileiros de Dermatologia
Background Mycosis fungoides is the commonest type of cutaneous T-Cell lymphoma. Janus kinases are intracellular tyrosine kinases that have recently been proven to have a crucial role in the pathogenesis and progression of several dermatological and ...
Heba Saed El-Amawy, Basma Mourad Mohamed Ali, Mohamed Moustafa Shareef, Lamia Elgarhy   +3 more
doaj   +3 more sources

Janus kinase inhibitors - their current applications and future prospects [PDF]

Farmacja Polska, 2022
Janus kinase inhibitors are a group of drugs that provide an alternative to conventional therapy for numerous diseases. The most studied drug of this group is tofacitinib.
Natalia Wierzbowska, Karolina Żurawska, Maciej Arciszewski, Arnold Kukowka, Bolesław Banach   +4 more
doaj   +1 more source

A JAK of all trades: how global phosphoproteomics reveal the Achilles heel of MPNs

Molecular & Cellular Oncology, 2021
While Janus-kinase (JAK)-inhibitors effectively reduce the inflammatory phenotype of myeloproliferative neoplasms (MPN), they do not affect disease burden or presence of the mutated clone to a major extent. Here, we show how Janus-kinase 2 (JAK2)-mutated
Tina M. Schnoeder, Florian Perner, Florian H. Heidel   +2 more
doaj   +1 more source

Understanding the efficacy of individual Janus kinase inhibitors in the treatment of ulcerative colitis for future positioning in inflammatory bowel disease treatment

Immunological Medicine, 2023
Recent studies have gradually elucidated the pathogenesis of inflammatory bowel disease; thus, the Janus kinase (JAK)-signal transducers and activators of transcription pathway are strongly involved in the pathophysiology of inflammatory bowel disease ...
Hiroshi Nakase
doaj   +1 more source

In silico method potential therapeutic use of Janus Kinase inhibitors as severe acute respiratory syndrome coronavirus 2 main protease inhibitors

Journal of the Scientific Society, 2023
Background: Coronavirus disease 2019 (COVID-19), it is an infectious respiratory disease caused by SARS corona virus 2 (SARS CoV-2). There are several reports of using JAK (Janus kinase)-inhibitors in persons with COVID-19 and the use of these decreased ...
Shankar Gharge, Sushmita I Hiremath, Akshata S Menasinakai, Mahesh S Palled   +3 more
doaj   +1 more source

An accurate, simple prognostic model consisting of age, JAK2, CALR, and MPL mutation status for patients with primary myelofibrosis

Haematologica, 2017
In most patients with primary myelofibrosis, one of three mutually exclusive somatic mutations is detected. In approximately 60% of patients, the Janus kinase 2 gene is mutated, in 20%, the calreticulin gene is mutated, and in 5%, the myeloproliferative ...
Uri Rozovski, Srdan Verstovsek, Taghi Manshouri, Vilma Dembitz, Ksenija Bozinovic, Kate Newberry, Ying Zhang, Joseph E. Bove, Sherry Pierce, Hagop Kantarjian, Zeev Estrov   +10 more
doaj   +1 more source

Janus Kinase Inhibitors in the Treatment of Alopecia Areata

Prague Medical Report, 2023
Alopecia areata is a disease of autoimmune origin which causes non scarring hair loss. The extent of alopecia varies from a small patch to complete scalp and body hair loss, which can have huge psychosocial impact for those affected. Treatment modalities
Athanasios J. Stefanis
doaj   +1 more source